SCHEMBL469690

SCHEMBL469690

c1ccc2c(-c3c[nH]nn3)n[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.56
IDO1 P14902 3/20 0.55
KDM4E B2RXH2 3/20 0.55
GAA P10253 2/20 0.55
ALDH1A1 P00352 2/20 0.55
TTK P33981 2/20 0.55
ALPL P05186 1/20 0.55
HPGD P15428 1/20 0.55
MAPK10 P53779 1/20 0.55
ITK Q08881 4/20 0.45
FGFR1 P11362 1/20 0.45
FLT1 P17948 1/20 0.45
AURKA O14965 1/20 0.45
PDPK1 O15530 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAP2K4 P45985 2/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1672674 0.77 IDO1 (0.78) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL4310603 0.75 LRRK2 (0.59) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL34465160 0.75 LRRK2 (0.59) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL1651151 0.72 LRRK2 (0.56) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL1328336 0.71 LRRK2 (1.00) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL30316298 0.71 LRRK2 (1.00) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL30768403 0.71 ALDH1A1 (1.00) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL855531 0.71 ALDH1A1 (1.00) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL31346909 0.71 LRRK2 (0.54) LRRK2IDO1KDM4EGAAALDH1A1
SCHEMBL18038340 0.71 LRRK2 (0.54) LRRK2IDO1KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042753-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2026-02-12 US disclosed
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient KAINOS MEDICINE, INC. (KR) 2026-01-27 US disclosed
US-12486260-B2 Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer MERCK PATENT GMBH (DE) 2025-12-02 US disclosed
EP-4520326-A2 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER Merck Patent GmbH (DE) 2025-03-12 EP disclosed
CN-114466844-B N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient 康佳诺医疗科技发展有限公司 2025-02-18 CN disclosed
EP-3924340-B1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2025-01-29 EP disclosed
CN-118955486-A Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer 默克专利股份公司 2024-11-15 CN disclosed
CN-113474334-B Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer 默克专利股份公司 2024-08-06 CN disclosed
US-20220348560-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT KAINOS MEDICINE, INC. (KR) 2022-11-03 US disclosed
US-11446274-B2 Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies DEL MAR PHARMACEUTICALS (BC) LTD. (CA) 2022-09-20 US disclosed
CN-103429585-A Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors MERCK SERONO SA 2013-12-04 CN disclosed
CN-103429585-A Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors MERCK SERONO SA 2013-12-04 CN disclosed
US-20130172280-A1 HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES CEMPRA PHARMACEUTICALS, INC. (US) 2013-07-04 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed
WO-2012034058-A1 HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES CEMPRA PHARMACEUTICALS, INC. (US) 2012-03-15 WO disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-06-07 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11446274-B2 Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies DCK, CDC7, DNMT1 LRRK2 1722/4885IDO1 2923/4885KDM4E 1079/4885
US-20260042753-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER KIT, ABL1, DSTYK LRRK2 422/4885IDO1 1784/4885KDM4E 522/4885
US-20130172280-A1 HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES Q6ZSR9, LSS, LCT LRRK2 2960/4885IDO1 3924/4885KDM4E 1222/4885
US-20220348560-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT IRAK4, IRAK1, IRAK2 LRRK2 784/4885IDO1 625/4885KDM4E 101/4885
US-12486260-B2 Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer KIT, TNNI3K, CILK1 LRRK2 3194/4885IDO1 1228/4885KDM4E 838/4885
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient IRAK4, IRAK1, IRAK2 LRRK2 1049/4885IDO1 1030/4885KDM4E 130/4885
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 LRRK2 483/4885IDO1 4093/4885KDM4E 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.